Publicacións nas que colabora con Javier Goicolea Ruigómez (40)

2022

  1. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study

    European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316

  2. Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 5, pp. e389-e396

  3. The TriClip system for edge-to-edge transcatheter tricuspid valve repair. A Spanish multicenter study

    Revista Espanola de Cardiologia, Vol. 75, Núm. 10, pp. 798-805

2021

  1. Percutaneous mitral valve repair: Outcome improvement with operator experience and a second-generation device

    Journal of Clinical Medicine, Vol. 10, Núm. 4, pp. 1-10

2020

  1. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with st-segment elevation myocardial infarction: Vascular healing outcomes from the magstemi trial

    EuroIntervention, Vol. 16, Núm. 11, pp. E913-E921

2019

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Twoyear follow-up of the SYNTAX II study

    EuroIntervention, Vol. 15, Núm. 3, pp. E244-A252

  2. MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design

    Catheterization and Cardiovascular Interventions, Vol. 93, Núm. 1, pp. 64-70

  3. Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients with ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial

    Circulation, Vol. 140, Núm. 23, pp. 1904-1916

2018

  1. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents

    JACC: Cardiovascular Interventions, Vol. 11, Núm. 10, pp. 981-991

  2. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    The Lancet, Vol. 392, Núm. 10151, pp. 940-949

2017

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

    European Heart Journal, Vol. 38, Núm. 42, pp. 3124-3134

  2. Outcomes and predictors of success and complications for paravalvular leak closure: An analysis of the Spanish realwOrld paravalvular LEaks closure (HOLE) registry

    EuroIntervention, Vol. 12, Núm. 16, pp. 1962-1968

2016

  1. Puncture Versus Surgical Cutdown Complications of Transfemoral Aortic Valve Implantation (from the Spanish TAVI Registry)

    American Journal of Cardiology, Vol. 118, Núm. 4, pp. 578-584

2014

  1. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: Results from the Metocard-CNIC trial (Effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction)

    Journal of the American College of Cardiology, Vol. 63, Núm. 22, pp. 2356-2362

  2. Response to letter regarding article, "effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial"

    Circulation

2013

  1. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction (METOCARD-CNIC) Trial

    Circulation, Vol. 128, Núm. 14, pp. 1495-1503

2012

  1. Comments on the ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. A report of the task force of the clinical practice guidelines committee of the Spanish society of cardiology

    Revista Espanola de Cardiologia, Vol. 65, Núm. 2, pp. 125-130

  2. Study design for the effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion (METOCARD-CNIC): A randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction

    American Heart Journal, Vol. 164, Núm. 4

2005

  1. Características y mortalidad del infarto agudo de miocardio tratado con intervencionismo coronario percutáneo primario en España. Resultados del Registro TRIANA 1 (TRatamiento del Infarto Agudo de miocardio eN Ancianos)

    Revista Espanola de Cardiologia, Vol. 58, Núm. 4, pp. 341-350

2004

  1. Complicaciones vasculares asociadas al acceso transradial para el cateterismo cardíaco

    Revista Espanola de Cardiologia, Vol. 57, Núm. 6, pp. 581-584